ACURX PHARMACEUTICALS INC (ACXP) Stock Earnings & Estimates
NASDAQ:ACXP - US00510M1045 - Common Stock
4.62 USD
-0.15 (-3.14%)
4.62 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | N/A 1,337.84% | N/A -26.60% | N/A 81.43% | N/A 30.51% | N/A 47.97% | |||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A -8.49% | N/A -8.70% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -5.93M | -4.6M 22.43% | -12.82M -178.70% | -12.09M 5.69% | -14.578M -20.58% | -14.103M 3.26% | N/A 29.47% | N/A -70.93% | N/A 10.16% | N/A 236.43% | N/A -49.75% | N/A 307.39% | N/A 49.69% | N/A 74.48% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A 29.59% | -1.14 95.30% | -0.87 23.68% | N/A -1,131.03% | N/A 8.48% | N/A 59.73% | N/A -313.95% | N/A 68.29% | N/A | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.34 -686.00% | -1.33 -733.00% | -1.21 45.06% | -1.15 39.29% | -0.75 43.89% | -0.78 41.45% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||
| EBITDA Q2Q % growth | -2.754M | -3.06M | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.206M -49.06% | -4.64M -66.80% | -3.871M -80.11% | -4.039M -77.96% | -4.376M -4.04% | -4.544M 2.07% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.89 -626.92% | -2.31 | 0.42 | 18.25% |
| Q1 2025 Q2Q % growth | -2.20 -685.71% | -3.06 | 0.86 | 28.10% |
| Q4 2024 Q2Q % growth | -0.16 56.76% | -0.18 | 0.02 | 12.85% |
| Q3 2024 Q2Q % growth | -0.17 29.17% | -0.20 | 0.03 | 16.67% |
| Q2 2024 Q2Q % growth | -0.26 7.14% | -0.22 | -0.04 | -15.86% |
| Q1 2024 Q2Q % growth | -0.28 -12.00% | -0.24 | -0.04 | -14.38% |
| Q4 2023 Q2Q % growth | -0.37 -32.14% | -0.27 | -0.10 | -39.52% |
| Q3 2023 Q2Q % growth | -0.24 25.00% | -0.28 | 0.04 | 12.85% |
| Q2 2023 Q2Q % growth | -0.28 -7.69% | -0.28 | 0.00 | -1.67% |
| Q1 2023 Q2Q % growth | -0.25 3.85% | -0.30 | 0.05 | 16.92% |
| Q4 2022 Q2Q % growth | -0.28 -27.27% | -0.36 | 0.08 | 21.57% |
| Q3 2022 Q2Q % growth | -0.32 30.43% | -0.29 | -0.03 | -12.04% |
| Q2 2022 Q2Q % growth | -0.26 55.17% | -0.36 | 0.10 | 27.17% |
| Q1 2022 Q2Q % growth | -0.26 | -0.34 | 0.08 | 22.76% |
| Q4 2021 Q2Q % growth | -0.22 | -0.41 | 0.19 | 46.08% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -813.97% | -122.03% | -2000% | -1318.92% |
| Revenue | N/A | N/A | 0% | -33.33% |